City of Hope

Ready to lead more effectively in today’s complex healthcare environment? The Matthew Loscalzo Leadership Training Series delivers practical strategies you can apply right away to strengthen teams, improve patient care and drive results. Each session tackles real leadership challenges, from building high-performing teams to navigating the often-overlooked realities of leadership. If you’re looking to grow your impact, this is built for you. Offered at no cost to you, with CME credits available. For more details and to register, go to: https://bit.ly/4uOVYwm

For 50 years, City of Hope has stood on a single promise to patients facing blood cancers: never stop advancing the science of cure, making it safer, more effective and within reach for all who need it.  That promise has guided more than 20,000 bone marrow/stem cell transplants, transformed patients into survivors and sparked discoveries that helped shape modern cellular therapy. It is the foundation of a program that helped change what was once impossible and established City of Hope as a national leader in blood cancer treatment.  “Early on in the BMT program,” said Stephen J. Forman, MD, director, Hematologic Malignancies Research Institute and the T Cell Therapeutics Research Laboratories, “we made a promise to keep pushing the science forward so that curing blood cancers would become safer, smarter and available to more patients. That commitment continues to guide us today.” See how City of Hope’s bone marrow and stem cell transplant program has evolved over five decades, advancing donor access, safety, supportive care and outcomes for patients across the nation. 

City of Hope was proud to bring together national leaders in cancer research and care for “The Next Frontier of Cancer Prevention and Care: The Microbiome,” a scientific symposium that examined how the microbiome may influence cancer risk, immune function, treatment response and long‑term health.    The symposium convened U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., National Cancer Institute (NCI) Director Jay Bhattacharya, M.D., Ph.D., senior officials from The National Institutes of Health, as well as researchers, clinicians, and leaders from City of Hope and other leading cancer centers for an executive roundtable on the microbiome and how to drive progress in the fight against cancer. We are grateful to the scientists and clinicians from these institutions who contributed to the symposium, driving forward meaningful progress in the fight against cancer: UT MD Anderson, Memorial Sloan Kettering Cancer Center, Fred Hutch, Penn Medicine, University of Pennsylvania Health System, Huntsman Cancer Institute, Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute, Children's Hospital Los Angeles (CHLA), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center.

In honor of Nurses Week, the water tower on our Duarte campus is glowing blue in every shade of scrubs worn by nursing teams across City of Hope. To our extraordinary nurses who shows up for patients every day: thank you. 💙 #NationalNursesWeek #ThePowerofNurses #OncologyNursingMonth

It’s a proud moment for City of Hope Chicago. Not only is it Hospital Week, a time to celebrate our employees and the exceptional care they provide our patients, but I am also honored to share that we have been named one of the Best Places to Work in U.S. Healthcare by Modern Healthcare! What makes this recognition meaningful is that it reflects our people and the culture we create every day through compassion, collaboration, and a shared commitment to patients. To everyone on our City of Hope Chicago team here in the hospital and at our Morton Grove and Downtown Chicago clinics, thank you for all you do to advance our mission. It is a privilege to lead alongside you.

New information—and misinformation—about breast cancer seems to surface every day. Join us for a live discussion on May 14th at 1pm ET exploring some of the biggest myths, facts, and questions in breast cancer today. Hear from BCRF researchers Veronica Jones, MD and Evanthia Roussos Torres, MD, PhD, moderated by Sadia Haque Zapp, as they break down what you really need to know about topics like AI-guided screening, hormone therapy and menopause, DCIS, GLP-1s, and more. Sign up for free here: https://bit.ly/4tCpR2x

Thank you Jay Asser and to HealthLeaders for highlighting an important challenge facing oncology today: innovation alone is not enough if patients cannot access it. At City of Hope, we believe the future of cancer care depends on stronger collaboration between academic medicine and community oncology — ensuring more patients can benefit from specialized expertise, clinical trials and breakthrough therapies closer to home. Proud of the physicians, researchers and partners helping expand access and rethink how we deliver cancer care across the country.

Cancer breakthroughs are arriving faster than at any point in human history. And yet, access to cancer care continues to be a barrier that many patients can’t overcome. That disconnect is becoming one of the defining challenges in oncology, according to Robert Stone, CEO of City of Hope, a Duarte, California-based comprehensive cancer center. While Stone is optimistic about the future of cancer treatment, he warns that access to those innovations varies widely. Stone estimated that only one in five cancer patients receive care at a comprehensive cancer center, leaving most patients dependent on community-based oncology providers. “Those of us who work at National Cancer Institute-designated comprehensive cancer centers, if we opened up our doors completely, there were no barriers to access, no geographic barriers, no insurance barriers, we could not make a dent,” Stone told HealthLeaders. “We don’t have enough capacity to impact materially that 80%.” In response, City of Hope is expanding physician networks and clinical trial access to connect community oncologists with subspecialty expertise. Stone says oncology leaders must rethink access, value, and collaboration as therapies become more specialized and complex. Read more on City of Hope's model designed to bridge the community-academic divide: https://lnkd.in/eyBNcv9r #CEO #cancer #healthcareaccess

TGen launches JAYseq, a 72 hour whole genome test for multiple myeloma TGen’s JAYseq™ test provides oncologists with a comprehensive molecular profile of a patient’s myeloma tumor using a single test. Powered by TGen’s ALTseq™ technology, JAYseq analyzes all 3 billion letters of a patient’s genome to identify key mutations, translocations, copy number changes, and the status of immunotherapy targets in 72 hours or less. This innovation helps physicians personalize treatment at diagnosis or relapse, reduces the burden of waiting, and brings precision medicine to myeloma patients. A major step forward for the myeloma community. TGen’s collaborations with the MMRF over the past 15 years on the MMRF’s Multiple Myeloma Research Consortium Genomics Initiative and CoMMpassSM Study proved the value of whole genome sequencing in multiple myeloma and built the expertise needed to make personalized treatment a reality for patients. #MultipleMyeloma #Genomics #PrecisionMedicine #TGen #CityOfHope #MMRF #ALTSeq TGen - Part of City of Hope City of Hope Multiple Myeloma Research Foundation - MMRF https://lnkd.in/gmg88vTg